SIAPS, in partnership with the FDA, NTP, and LCP-NCPR, conducted a readiness assessment to determine the current information technology (IT) infrastructure, human resources, processes, and data management and quality control mechanisms available and to identify gaps in the current PV recording and reporting of patients in the seven Programmatic Management of Drug-Resistant TB (PMDT) treatment facilities implementing the 9MTR for multidrug-resistant (MDR)-TB study. The results of this assessment will provide inputs for developing the PViMS implementation plan.
Archive | PViMSRSS feed for this section
Georgia is one of the first countries to benefit from the USAID‑Janssen Therapeutics bedaquiline (BDQ) donation program. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines are being used for the treatment of MDR-TB patients, as well as TB patients who have […]
An integrated approach to monitoring the safety of medicines that includes both active surveillance and spontaneous reporting is essential to a well-functioning pharmaceutical sector. Active surveillance is particularly important to support the introduction of new essential medicines in low-and middle-income countries, where regulatory systems are often still developing and need support. In such resource-limited settings, […]